Cross A S, Opal S M, Palardy J E, Bodmer M W, Sadoff J C
Division of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
J Infect Dis. 1993 Jan;167(1):112-8. doi: 10.1093/infdis/167.1.112.
Immunotherapy has been shown to be an effective adjuvant in the management of septic shock. A neutropenic rat model of septic shock induced by infection with Pseudomonas aeruginosa 12.4.4 (Fisher immunotype 6) was used to determine the relative efficacy of single, double, and triple combination immunotherapy. A Pseudomonas O serotype-specific, opsonophagocytic monoclonal antibody (MAb), polyclonal J5 antiserum, and a MAb directed against tumor necrosis factor-alpha (TNF) were studied as single therapy and in combination. The combination of all three immunotherapeutic agents resulted in a 77% survival rate (33/43 animals). This level of protection was superior to that achieved with any combination of two antibody treatments (50%-60% survival; P = .029) or single antibody therapy (25%-43% survival; P < .001) or compared with a control group (0/25 survivors; P < .0001). Immunotherapy directed against multiple steps of the septic process is more active than single or double antibody regimens and may offer an improved approach to the adjunctive treatment of septic shock.
免疫疗法已被证明是治疗感染性休克的一种有效辅助手段。采用铜绿假单胞菌12.4.4（费舍尔免疫型6）感染诱导的中性粒细胞减少性感染性休克大鼠模型，以确定单一、双重和三联组合免疫疗法的相对疗效。研究了一种铜绿假单胞菌O血清型特异性的调理吞噬单克隆抗体（MAb）、多克隆J5抗血清和一种针对肿瘤坏死因子-α（TNF）的单克隆抗体，分别作为单一疗法及联合疗法进行研究。三种免疫治疗药物联合使用的动物存活率为77%（43只动物中有33只存活）。这种保护水平优于任何两种抗体治疗组合（存活率为50%-60%；P = 0.029）或单一抗体治疗（存活率为25%-43%；P < 0.001），与对照组相比也更优（25只动物中无存活；P < 0.0001）。针对感染过程多个步骤的免疫疗法比单一或双重抗体方案更有效，可能为感染性休克的辅助治疗提供一种改进方法。
